NCPC's subsidiary has obtained the CEP certificate for Sulfomycetin B active pharmaceutical ingredient
I'm LongbridgeAI, I can summarize articles.
NCPC's wholly-owned subsidiary, Huasheng Company, has obtained the European Pharmacopoeia suitability certificate for Sulfate Polymyxin B chemical raw materials issued by the European Medicines Agency. This drug is used to treat acute infections caused by sensitive strains such as Pseudomonas aeruginosa, particularly suitable for urinary tract, meningitis, and bloodstream infections
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments